gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 12 Nov 2015.

Bruton agammaglobulinemia tyrosine kinase

Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, Syk, V1a, Tec
Papers using Btk antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
von Lindern Marieke et al., In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Nürnberg Bernd et al., In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
El Khoury Joseph, In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Nukiwa Toshihiro et al., In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on Btk
A phase I clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Salles et al., Leicester, United Kingdom. In Blood, 05 Dec 2015
UNASSIGNED: We report the results of a multi-center Phase I dose escalation study of the selective BTK inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.
Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Krappmann et al., München, Germany. In Oncotarget, 02 Dec 2015
Inhibition of BTK by Ibrutinib has been shown to kill ABC DLBCL cells that carry activating mutations in the BCR adaptor CD79.
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Hamadani et al., Milwaukee, United States. In Bone Marrow Transplant, 30 Nov 2015
The last decade has seen a proliferation of clinical studies looking at the prevention of post-auto-HCT therapy failure with various maintenance strategies.
Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.
Sparidans et al., Utrecht, Netherlands. In J Pharm Biomed Anal, 27 Nov 2015
At room temperature, ibrutinib showed a not earlier described instability, and revealed rapid degradation at 37°C.
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.
Spurgeon et al., Salt Lake City, United States. In Ther Adv Hematol, 31 Oct 2015
Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway.
Advances in first-line treatment of chronic lymphocytic leukemia current recommendations on management and first-line treatment by the german cll study group (gcllsg).
Hallek et al., Köln, Germany. In Eur J Haematol, 02 Oct 2015
An increasing understanding of the disease biology led to the development of targeted drugs for the treatment of CLL, such as the BTK and PI3K inhibitors ibrutinib or idelalisib.
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Burger et al., Houston, United States. In Biochim Biophys Acta, Aug 2015
Novel small molecule inhibitors, including the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and the phosphoinositide-3-kinase delta (PI3Kδ) inhibitor idelalisib, target BCR signaling and have become the most successful new therapeutics in this disease.
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Advani et al., United States. In N Engl J Med, May 2015
MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.
A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Pan et al., Shenzhen, China. In Sci Rep, Dec 2014
As a critical regulator of the B-cell receptor signaling pathway, Bruton's tyrosine kinase (Btk) has attracted intensive drug discovery efforts for treating B-cell lineage cancers and autoimmune disorders.
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Melnick et al., In J Clin Invest, Dec 2014
Functional assays revealed that teHSP90 facilitates BCR signaling dynamics by enabling phosphorylation of key BCR signalosome components, including the kinases SYK and BTK.
Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms.
Schmidt-Hieber et al., Köln, Germany. In Biomark Insights, Dec 2014
Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
O'Brien et al., Houston, United States. In Lancet Oncol, Sep 2014
BACKGROUND: Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL).
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Oki et al., New York City, United States. In Lancet Oncol, Aug 2014
Pharmacodynamic data showed Bruton's tyrosine kinase was fully occupied (>90% occupancy) at the recommended phase 2 dose.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
RESONATE Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Aug 2014
We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
Ibrutinib treatment of CLL: the cancer fights back.
Staudt et al., Bethesda, United States. In Cancer Cell, Aug 2014
Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).
Tyrosine kinase Btk is required for NK cell activation.
Cao et al., Shanghai, China. In J Biol Chem, 2012
Data suggest a role of tyrosine kinase Btk in the regulation of immune cell unctions and innate inflammatory response.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
Nore et al., Huddinge, Sweden. In Mol Cell Biol, 2012
mapped the interaction site to the C terminus of the Btk SH3 domain
Single-chain variable fragment intrabody impairs LPS-induced inflammatory responses by interfering with the interaction between the WASP N-terminal domain and Btk in macrophages.
Kitani et al., Tsukuba, Japan. In Biochem Biophys Res Commun, 2012
These observations strongly suggest that the phosphorylation of WASP by Btk plays a pivotal role in transducing the LPS signaling pathway in macrophages.
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
Hendriks et al., Rotterdam, Netherlands. In Blood, 2012
Transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
Lam et al., Singapore, Singapore. In Proc Natl Acad Sci U S A, 2012
BTK plays a critical role in initiating TLR3 signaling.
share on facebooktweetadd +1mail to friends